Joy Bessenger Email

SVP, Investor Relations and Corporate Strategy . IMV

Dartmouth,

Location

LinkedIn

Current Roles

Employees:
38
Revenue:
$20M
About
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company?s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. For more information, please connect at: www.imv-inc.com
IMV Address
130 Eileen Stubbs Ave
Dartmouth, null
IMV Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.